Burzynski Clinic
Burzynski Clinic is a privately-held Houston oncology center founded in 1977 that provides personalized cancer treatment built around proprietary Antineoplaston peptides, serving advanced and treatment-resistant cancer patients, with a focus on brain tumors, via in-person and telemedicine care.
- Company typePrivate
- Founded1977
- HeadquartersHouston, United States
- Headcount51–100
- GTM typeB2C
- OfferingServices
What Burzynski Clinic does
Burzynski Clinic is a privately-held oncology treatment center founded in 1977 in Houston, Texas by Dr. Stanislaw R. Burzynski, a Polish-born physician and biochemist. The clinic specializes in personalized cancer treatment centered on Antineoplaston Therapy (ANP), a proprietary approach using peptides A10 and AS2-1 designed to target over 400 mutated genes, and has cumulatively treated more than 10,000 patients. Dr. Burzynski holds 245 patents worldwide covering ANP compounds and related methodologies, and the clinic has conducted 72 clinical trials through its wholly-owned research subsidiary, the Burzynski Research Institute.
Burzynski Clinic firmographics
Firmographics- Name
- Burzynski Clinic
- Legal name
- Burzynski Clinic
- Website
- https://burzynskiclinic.com
- Company type
- Private
- Founded year
- 1977
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Burzynski Clinic is a privately-held Houston oncology center founded in 1977 that provides personalized cancer treatment built around proprietary Antineoplaston peptides, serving advanced and treatment-resistant cancer patients, with a focus on brain tumors, via in-person and telemedicine care.
- Ownership category
- akta.pro rank
Burzynski Clinic industry classification
Industry- Product category
- Specialty Oncology / Personalized Cancer Treatment Services
- NAICS
- Offices of Other Health Practitioners (6213), Medical and Diagnostic Laboratories (62151)
- SIC
- Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Health Services (8000)
- akta.pro primary industry
- Medical Oncology (HLAKAFAB)
- akta.pro secondary industries
- Neuro-Oncology (HLAKAFAH), Oncology Telemedicine Platforms (HLALAGAH), Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK), Oncology Specialty Pharmaceuticals (HLAIACAA)
Keywords
Where Burzynski Clinic is headquartered
LocationHeadquarters
- HQ city
- Houston
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Burzynski Clinic business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Clinical Treatment Services: Revenue generated from providing personalized cancer treatment services, including consultations, targeted therapies, and ongoing patient care. The clinic operates as a medical facility providing treatment to cancer patients.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels3 records
Burzynski Clinic product offering
Product offeringCore offering
The Burzynski Clinic provides personalized, targeted cancer treatment services to patients with advanced, recurrent, or treatment-resistant cancers, primarily brain tumors. Its core offering combines proprietary Antineoplaston Therapy (ANP) using compounds A10 and AS2-1, FDA-approved targeted medications (including Sodium Phenylbutyrate), and molecular/genetic testing to design individualized treatment plans that target over 400 mutated genes. Treatment is delivered through in-person consultations at the Houston clinic, supported by 24/7 physician access, telemedicine, and home-visit oncology services.
Product overview
The Burzynski Clinic offers a unified portfolio of innovative cancer treatment services centered on Antineoplaston Therapy (ANP), their proprietary treatment developed by Dr. Stanislaw Burzynski. The core offering consists of Personalized Cancer Treatment Plans that integrate Antineoplastons A10 and AS2-1 with targeted therapies including FDA-approved Sodium Phenylbutyrate (PB). Supporting services include Diagnostic & Monitoring Services (molecular and genetic testing), Concierge-Level Oncologic Care (24/7 support, telemedicine, home visits), and Advanced Imaging coordination. The treatment approach focuses on personalized precision medicine, targeting over 400 mutated genes identified through genomic profiling, with the goal of minimizing toxicity while maximizing efficacy. The clinic has treated patients since 1977 and operates FDA-approved clinical trials.
Differentiator
Problem solved
Functional benefit
Products and services
- Antineoplaston Therapy (ANP) Proprietary cancer treatment developed by Dr. Stanislaw Burzynski using the Antineoplaston compounds A10 and AS2-1 — naturally occurring peptides designed to target over 400 mutated genes and induce apoptosis in cancer cells while sparing healthy tissue. Used for patients with advanced, recurrent, or treatment-resistant cancers, especially brain tumors.
- Personalized Cancer Treatment Plans Customized oncology treatment programs tailored to each patient's genetic profile, tumor characteristics, and health needs, using genomic testing and molecular profiling to identify the optimal combination of Antineoplastons, FDA-approved targeted medications, and supportive care.
- Diagnostic & Monitoring Services Advanced molecular and genetic testing services to identify specific mutations and biomarkers in the patient's cancer, enabling precise treatment targeting and ongoing disease monitoring throughout the treatment journey. Includes advanced imaging coordination.
- Concierge-Level Oncologic Care VIP-style patient care program that provides 24/7 access to the medical team, compassionate nursing support, streamlined scheduling, telemedicine consultations, home visits, and mobile diagnostics for select cases.
- Home & Remote Oncology Services Telemedicine consultations, home visits, and mobile diagnostics that deliver cancer care in patients' homes for those unable to travel to the Houston clinic or who prefer home-based treatment and monitoring.
- Targeted Therapy (FDA-approved combination) Drug therapy targeting specific genes or proteins in cancer cells using FDA-approved medications such as Sodium Phenylbutyrate, combined with Antineoplastons to address genes not covered by ANP therapy alone.
Companies that use Burzynski Clinic
Customer profileNamed customers6 records
Segments2 records
Ideal customer profiles2 records
Burzynski Clinic technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Burzynski Clinic partnerships and signals
Strategic signalScale indicators4 records
Recent moves5 records
Expansion highlights5 records
Burzynski Clinic competitors and assessment
Company assessmentEmerging players
- Riordan Clinic: Integrative and alternative medicine clinic in Wichita, KS offering non-conventional approaches to cancer care including nutritional and immune-based therapies. Comparable to Burzynski Clinic in operating outside the mainstream oncology establishment with self-pay models and offering alternative cancer treatments, though without a proprietary drug therapy like ANP.
- Hope4Cancer Treatment Centers: Alternative and integrative cancer treatment center with locations in Mexico and Bahamas, treating advanced cancer patients with non-conventional therapies. Comparable to Burzynski Clinic in serving international patients with refractory cancers who have exhausted conventional options, with similar self-pay business model and emphasis on personalized treatment plans.
- Issels Immuno-Oncology: Specialty clinic offering personalized immunotherapy and integrative cancer treatment programs for advanced and treatment-resistant cancers. Comparable to Burzynski Clinic in serving self-pay patients with refractory cancers through proprietary non-standard protocols, including combination approaches with targeted biological therapies.
Broad incumbents
- Mayo Clinic Cancer Center: Multi-site comprehensive cancer center treating complex and advanced oncology cases including brain tumors. Comparable to Burzynski Clinic in serving patients seeking specialized care for treatment-resistant cancers, though operating under standard-of-care protocols with extensive insurance and academic research infrastructure.
- Moffitt Cancer Center: Florida-based NCI-designated Comprehensive Cancer Center with strong personalized medicine and molecular profiling programs. Comparable to Burzynski Clinic in emphasizing genomic-based treatment selection and serving advanced/refractory cancer patients, but within an academic research framework with conventional modalities.
- Memorial Sloan Kettering Cancer Center: Premier academic cancer center in New York offering specialized treatment for advanced and rare cancers including brain tumors. Comparable to Burzynski Clinic in treating complex oncology cases (including pediatric brain tumors) but with vastly broader institutional resources, FDA-standard treatment protocols, and insurance acceptance.
- Stanford Cancer Institute: Academic comprehensive cancer center with active precision oncology and brain tumor programs. Comparable to Burzynski Clinic in offering genetically-informed personalized cancer treatment, including for advanced brain tumors, though through FDA-approved targeted therapies and clinical trial infrastructure.
- MD Anderson Cancer Center: One of the world's largest comprehensive cancer centers based in Houston, TX. While MD Anderson operates at vastly greater scale and offers the full spectrum of standard oncology care, it is the most geographically proximate major cancer center to Burzynski Clinic and competes for the same advanced/refractory oncology patient population in the Texas medical marketplace.
- Dana-Farber Cancer Institute: Harvard-affiliated specialty cancer center with strong pediatric and adult brain tumor programs. Directly comparable to Burzynski Clinic in treating refractory and advanced oncology cases with personalized approaches, but operates as a research-driven academic institution with conventional treatment modalities and broad insurance participation.
Direct peers
- Cancer Treatment Centers of America (City of Hope): National network of specialty cancer hospitals now operating under City of Hope, focused on personalized, patient-centric oncology care for advanced and complex cases. Comparable to Burzynski Clinic in delivering concierge-style, integrated oncology services to patients willing to travel for specialized treatment, though operating at much larger scale and using conventional modalities.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Burzynski Clinic social profiles
Digital presenceBurzynski Clinic financial estimates
Financial estimateRevenue estimate
Valuation estimate
Burzynski Clinic leadership team
Management profileNumber of profiles
Profiles6 records
Burzynski Clinic subsidiaries and ownership
Company hierarchySubsidiaries1 record
Burzynski Clinic funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Burzynski Clinic M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Burzynski Clinic
What does Burzynski Clinic do?
The Burzynski Clinic provides personalized, targeted cancer treatment services to patients with advanced, recurrent, or treatment-resistant cancers, primarily brain tumors. Its core offering combines proprietary Antineoplaston Therapy (ANP) using compounds A10 and AS2-1, FDA-approved targeted medications (including Sodium Phenylbutyrate), and molecular/genetic testing to design individualized treatment plans that target over 400 mutated genes. Treatment is delivered through in-person consultations at the Houston clinic, supported by 24/7 physician access, telemedicine, and home-visit oncology services.
Is Burzynski Clinic a public or private company?
Burzynski Clinic is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Burzynski Clinic founded?
Burzynski Clinic was founded in 1977. It employs 51 to 100 people.
Where is Burzynski Clinic based?
Burzynski Clinic is headquartered in Houston, United States, in the North America region.
How does Burzynski Clinic make money?
One revenue line is on record: clinical Treatment Services.
Who are Burzynski Clinic's main competitors?
Emerging players on record are Riordan Clinic, Hope4Cancer Treatment Centers and Issels Immuno-Oncology. Broad incumbents are Mayo Clinic Cancer Center, Moffitt Cancer Center, Memorial Sloan Kettering Cancer Center, Stanford Cancer Institute, MD Anderson Cancer Center and Dana-Farber Cancer Institute. Cancer Treatment Centers of America (City of Hope) is listed as a direct peer.
Does Burzynski Clinic have an API?
No public API is recorded for Burzynski Clinic.
What industry is Burzynski Clinic in?
Burzynski Clinic's product category is Specialty Oncology / Personalized Cancer Treatment Services. Its primary akta.pro industry code is HLAKAFAB, Medical Oncology, with a secondary code of HLAKAFAH, Neuro-Oncology. Its NAICS code is 6213 and its SIC code is 8011.